RxDoctor Payments Data

Jacqueline Reiss, MD

Allergy & Immunology · Chesterfield, MONPI 1497748909

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $409 of the $649 with a category attached, or 63.0%. 13 manufacturers reported payments, led by Pfizer at 36.8% of the total. Reporting peaked in 2019 at $224 and has fallen 69.5% since, to $68 in 2025. That places this record below the midpoint for allergy & immunology clinicians in MO, where the typical reported total is $1,710.

$649in general payments, 2019–2025

Across 37 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$239
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Regeneron Healthcare Solutions, Inc.$80
  • Novartis$47
  • Genentech USA, Inc.$32
  • CSL Behring$32
  • plus $105 from 7 others

What the payments were for

  • Food & beverage$40963%
  • Education$24037%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$649 in reported general payments places this provider in the 30th percentile of 61 allergy & immunology providers in Missouri.

See all allergy & immunology providers in Missouri

Medicare billing

Part B allowed, 2024
$37,384
Medicare patients
125
Services billed
2,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$97,268
XolairOmalizumab14$39,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$24,905
Spiriva RespimatTiotropium Bromide25$24,268
SymbicortBudesonide/Formoterol Fumarate21$8,130
Arnuity ElliptaFluticasone Furoate14$5,873
BreynaBudesonide/Formoterol Fumarate25$3,667
Azelastine Hcl91$3,375
Qvar RedihalerBeclomethasone Dipropionate11$2,910
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,829
Albuterol Sulfate HfaAlbuterol Sulfate43$1,204
Ipratropium Bromide35$1,048
Epinephrine13$1,047
Montelukast Sodium100$969
Levocetirizine Dihydrochloride12$825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$32$97,26813 claims
AstraZenecaSymbicort$17$8,13021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 61 allergy & immunology providers in Missouri.

Other allergy & immunology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →